. 2015 Apr 2;1(3):134–143. doi: 10.1002/cjp2.15

Table 2.

Comparison of PFS by original Colorado scoring versus ReadMax scoring in the SATURN study (ReadMax population)

		HR (p value)
	Comparison	Colorado scoring	ReadMax scoring
All patients with data (n = 201)	Erlotinib FISH+ vs erlotinib not FISH+	0.73 (p = 0.136)	0.53 (p = 0.003)
All patients with data (n = 201)	Erlotinib FISH+ vs placebo FISH+	0.67 (p = 0.04)	0.52 (p = 0.004)
FISH‐positive (%)		55	38
EGFR WT subgroup (n = 131)	Erlotinib FISH+ vs erlotinib not FISH+	1.20 (p = 0.48)	0.65 (p = 0.143)
EGFR WT subgroup (n = 131)	Erlotinib FISH+ vs placebo FISH+	1.02 (p = 0.94)	0.63 (p = 0.185)
FISH‐positive (%)		51	27

WT, wild‐type